Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma US has launched its first product in the US, making the systemic anti-fungal agent Mycamine available to hospitals nationwide.
Subscribe to our email newsletter
The FDA approved Mycamine (micafungin sodium) in March 2005 for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and the treatment of esophageal candidiasis.
Mycamine is the first product to be launched by Astellas Pharma US, which was recently formed through the merger of Fujisawa Healthcare and Yamanouchi Pharma America.
“The launch and availability of Mycamine underscores Astellas’ commitment to bringing innovative products to market,” stated Kurt Lewis, senior vice president of marketing and sales at Astellas Pharma US. “Mycamine is the first new product for recently formed Astellas Pharma US and an important step in solidifying our presence in the anti-infective market.”
Astellas Pharma US recently signed a co-promotion agreement with Roche Pharmaceuticals. Under the agreement, Roche will augment Astellas Pharma’s dedicated hospital sales force in the promotion of Mycamine throughout the US.